| Property |
Value |
| Category |
Presynaptic Monoamine Transporter |
| Target |
Vesicular Monoamine Transporter 2 |
| Sample Type |
Brain PET imaging, post-mortem tissue |
| Diseases |
Parkinson's Disease, Huntington's Disease, DLB, MSA |
| Sensitivity |
High |
| Specificity |
High for dopaminergic terminals |
Vesicular Monoamine Transporter 2 (VMAT2) is a transmembrane protein responsible for packaging monoamine neurotransmitters (dopamine, norepinephrine, serotonin, histamine) into synaptic vesicles. VMAT2 serves as a highly specific marker for monoaminergic neurons and terminals, making it an excellent biomarker for in vivo imaging of dopaminergic neuronal integrity in Parkinson's disease and related disorders.
VMAT2 is encoded by the SLC18A2 gene (chromosome 10q25.3), a member of the vesicular monoamine transporter family. The protein has 12 transmembrane domains and functions as an proton-dependent antiporter. Each VMAT2 molecule can transport approximately 100 monoamine molecules per vesicular cycle.
- High expression: Substantia nigra pars compacta (dopaminergic neurons), locus coeruleus (noradrenergic neurons), dorsal raphe (serotonergic neurons)
- Moderate expression: Hypothalamus, amygdala, cortical regions
- Low expression: Most peripheral tissues
VMAT2 imaging provides critical information about:
- Presynaptic dopaminergic integrity: VMAT2 binding correlates with surviving dopamine neurons
- Disease progression: Progressive loss of VMAT2 binding in striatum
- Diagnostic accuracy: Distinguishes PD from non-neurodegenerative tremor disorders
- Prodromal detection: Reduced VMAT2 in REM sleep behavior disorder (RBD) predicts PD conversion
| Marker |
What it Measures |
Advantage |
| VMAT2 |
Vesicular dopamine storage |
Less affected by compensatory changes |
| DAT |
Dopamine reuptake |
Earlier detection |
| FDOPA |
Dopamine synthesis |
Direct metabolic flux |
¶ PET Ligands for VMAT2
| Ligand |
Half-life |
Applications |
| [^11C]DTBZ |
20 min |
Research, clinical trials |
| [^18F]FP-DTBZ |
110 min |
Clinical research |
| [^18F]AV-133 |
110 min |
Diagnostic imaging |
- Diagnostic confirmation: Differentiates parkinsonian syndromes from essential tremor
- Severity staging: Correlates with Hoehn & Yahr stage and UPDRS scores
- Progression monitoring: Annual loss of ~4-8% VMAT2 binding
- Therapeutic monitoring: Effects of dopamine agonists on disease progression
VMAT2 binding is reduced in:
- Premanifest HD gene carriers
- Early manifest HD patients
- Correlates with motor symptoms and disease burden score
- VMAT2 loss in caudate distinguishes DLB from AD
- Helps differentiate DLB from Parkinson's Disease dementia
- More severe VMAT2 reduction than PD
- Correlates with autonomic dysfunction severity
VMAT2 imaging is used to:
- Identify suitable patients for dopaminergic therapies
- Monitor neuroprotective drug efficacy
- Evaluate stem cell and gene therapy outcomes
- Stratify patients for clinical trials
The study of Vmat2 Dopaminergic Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
VMAT2 transports monoamines into synaptic vesicles:
- Substrate recognition: Dopamine, serotonin, norepinephrine, histamine
- Proton gradient: V-ATPase provides energy
- Vesicle filling: Concentrates neurotransmitters 10-fold
- Activity regulation: Phosphorylation affects function
- VMAT2 (SLC18A2): Primary neuronal isoform
- VMAT1 (SLC18A1): Peripheral, less specific
- Differentiation: VMAT2 is neuron-specific
| Tracer |
Target |
Application |
| FP-CIT (DaTscan) |
DaT |
Dopaminergic terminals |
| β-CIT |
SERT, DaT |
Dopamine/serotonin transport |
| PE2I |
DaT |
High specificity |
| 18F-AV-133 |
VMAT2 |
VMAT2 quantification |
- FDA approved: 2011
- Indications: Differential diagnosis of parkinsonism
- Sensitivity: 95% for Parkinsonian syndromes
- Specificity: 80-90% for PD vs essential tremor
- Presynaptic marker: Measures intact dopaminergic terminals
- Braak staging: Correlates with disease stage
- Prodromal detection: Can detect pre-motor PD
- Disease progression: Annual decline ~4-8%
| Condition |
DaTscan Result |
| Parkinson's Disease |
Abnormal (reduced) |
| Progressive Supranuclear Palsy |
Abnormal |
| Multiple System Atrophy |
Abnormal |
| Corticobasal Degeneration |
Abnormal |
| Essential Tremor |
Normal |
| Psychogenic Parkinsonism |
Normal |
- DLB vs AD: DaTscan abnormal in DLB
- Fluctuating cognition: Correlates with imaging
- Visual hallucinations: Associated with loss
- Usually normal: Spares dopaminergic system
- DLB comorbidity: Distinguishes mixed pathology
- Research use: Excludes Lewy body pathology
- Depression: Altered SERT binding (not VMAT2)
- ADHD: Dopamine transporter studies
- Addiction: Amphetamine effects on VMAT2
- Functional variants: Affect transport efficiency
- Disease associations: PD risk modification
- Pharmacogenetics: Tetrabenazine response
- Post-mortem brain: Reduced in PD substantia nigra
- Peripheral blood: Biomarker potential
- iPSC models: Disease modeling applications
| Drug |
Use |
Mechanism |
| Tetrabenazine |
Chorea (HD) |
Deplete dopamine |
| Deutetrabenazine |
HD, TD |
Improved tolerability |
| Valbenazine |
TD |
VMAT2 modulation |
- VMAT2 enhancement: Increase monoamine storage
- Gene therapy: AAV-VMAT2 delivery
- Small molecule activators: Under development
- Higher specificity: VMAT2 vs DAT/SERT
- Quantification: Better kinetic modeling
- Early detection: Prodromal biomarkers
- Combined imaging: VMAT2 + FDG patterns
- CSF biomarkers: Correlate with imaging
- Clinical algorithms: Integrated diagnostic tools
- Frey KA, et al. (1996). Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 40(6): 873-884. PMID:9007089
- Bohnen NI, et al. (2006). Frequency of cholinergic and caudate nucleus dopaminergic deficits in Parkinson's disease. Brain. 129(Pt 7): 1740-1751. PMID:16674943
- Stoessl AJ, et al. (2014). Biomarkers for Parkinson's disease: an update. Mov Disord. 29(14): 1662-1670. PMID:25155557
- Pagano G, et al. (2018). VMAT2 and dopamine neuron loss in parkinsonism. Mov Disord. 33(5): 710-711. PMID:29624757
- Wilson JM, et al. (1996). Altered vesicular dopamine storage in Parkinson's disease: a premature step. Neurology. 47(2): 493-498. PMID:8757038
- Kordower JH, et al. (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 136(Pt 8): 2419-2431. PMID:23842588
- Nandhagopal R, et al. (2009). PET measurement of dopamine and serotonin transporters or receptors in Parkinson disease. Neurology. 72(24): 2144-2150. PMID:19227956
- Brooks DJ, et al. (2010). Imaging of dopaminergic dysfunction in early Parkinson's disease. J Neuroimaging. 20(3): 229-234. PMID:19500195